Sanctura Xr

(trospium)

ApprovedSmall molecule

VVitae Pharmaceuticals Inc., an Allergan affiliate

Sanctura Xr is one of 25 small molecule programs targeting Overactive Bladder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Overactive BladderActive, not recruiting

Urgency Urinary IncontinenceCompleted

Overactive BladderPreclinical

Active, not recruiting

Urgency Urinary IncontinenceApproved

Completed

Competition

Competitive Landscape

27 competitors in Overactive Bladder

#DrugCompanyPhaseTrials

Myrbetriq

Astellas

Approved

45 2

Vesicare

Astellas

Approved

47 3

Detrol La

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

21 4

Toviaz

Pfizer

Approved

16 5

Flomax

Sanofi

Approved

2 6

Cialis

Eli Lilly

Approved

2 7

Enablex

AbbVie

Approved

8 8

Activella

Eli Lilly

Approved

1 9

Cipro

Bayer

Approved

1 10

Oxytrol

WWim Janssens

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Overactive Bladder2 trials

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Completed· Astellas logo

Astellas··NCT03602508·5,589 enrolled

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Completed· Astellas logo

Astellas··NCT03572231·805 enrolled

Urgency Urinary Incontinence1 trial

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

Completed·BBecky Clarkson·Phase 4·NCT04227184·207 enrolled

Regulatory

FDA Approval Timeline[4]

May 28, 2004

SANCTURA

NDA NDA021595

Aug 3, 2007

SANCTURA XR

NDA NDA022103

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for trospium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — trospium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for trospium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA022103). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Vitae Pharmaceuticals Inc., an Allergan affiliate company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: VVitae Pharmaceuticals Inc., an Allergan affiliate

Sanctura Xr

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Overactive Bladder2 trials

Urgency Urinary Incontinence1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News